Premium
Urinalysis of MMX‐mesalazine as a tool to monitor 5‐ASA adherence in daily IBD practice
Author(s) -
Römkens Tessa E. H.,
Morsche Rene,
Peters Wilbert,
Burger David M.,
Hoentjen Frank,
Drenth Joost P. H.
Publication year - 2018
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13462
Subject(s) - urinalysis , mesalazine , medicine , urine , ulcerative colitis , dosing , disease
Adherence is pivotal but challenging in ulcerative colitis (UC) treatment. Many methods to assess adherence are subjective or have limitations. (Nac‐)5‐aminosalicylic acid (5‐ASA) urinalysis by high‐performance liquid chromatography (HPLC) seems feasible and reproducible in healthy volunteers. We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac‐)5‐ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care. Twenty‐nine patients (51.7% male, mean age 52 ± 11 years) were included (median FU 9 months) and weekly spot urine samples were collected. We found large variation in spot (Nac‐)5‐ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5‐ASA. In conclusion, spot (Nac‐)5‐ASA urinalysis is not applicable to assess 5‐ASA adherence in daily IBD care.